Puma Biotechnology
PBYI
171 hedge funds and large institutions have $4.39B invested in Puma Biotechnology in 2017 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 25 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
20% more capital inflows, than outflows
Capital inflows: $663M | Capital outflows: $551M
19% more call options, than puts
Call options by funds: $87.7M | Put options by funds: $74M
11% more funds holding
Funds holding: 154 → 171 (+17)
2.49% more ownership
Funds ownership: 96.09% → 98.59% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$170M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$61.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$37.5M |
| 4 |
Polar Capital
London,
United Kingdom
|
+$33.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$158M |
| 2 |
Millennium Management
New York
|
-$91.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$74.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$29.1M |
PBYI Hedge Fund Activity: Q3 2017 in Review
171 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2017, worth a combined $4.39B — up 41% from $3.1B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PBYI positions and 25 closed out — a net gain of 17 holders — while 62 added to existing stakes and 48 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $170M. The largest seller was Wellington Management Group, cutting an estimated $158M.
- 171 institutional investors held Puma Biotechnology (PBYI) as of Q3 2017, up from 154 in Q2 2017.
- Funds reported $4.39B of Puma Biotechnology stock for Q3 2017, up 41% quarter-over-quarter.
- 42 funds opened new Puma Biotechnology positions in Q3 2017 and 25 closed out, a net change of +17 holders.
- The largest Puma Biotechnology buyer in Q3 2017 was T. Rowe Price Associates, an estimated $170M added.
- The largest Puma Biotechnology seller in Q3 2017 was Wellington Management Group, an estimated $158M sold.
Based on aggregated 13F filings for Q3 2017.